24 results about "Drug responsiveness" patented technology

Disclosed herein are methods of treatment and methods of evaluating individuals to identify and measure biomarkers and / or states of the individuals indicative of drug responsiveness to one or more 5-HT receptor agonist.

The invention discloses a humanized osteoporosis mouse model and a construction method thereof, and belongs to the technical field of biotechnology and animal models. The invention aims at the core defects of large species difference, insufficient humanization degree, low pathological simulation degree, unstable phenotype and the like of the existing osteoporosis model. The humanized osteoporosis mouse model is constructed through five core steps of experimental animal pretreatment, collagen-nano hydroxyapatite bionic scaffold preparation and cell pre-implantation, immune-bone metabolism double-derived system construction, progressive osteoporosis induction and model identification and verification. According to the method, double-person origination of immune and bone metabolism systems is realized for the first time, the colonization rate and survival time of human cells are greatly improved, the pathological process of clinical postmenopausal osteoporosis is accurately simulated, the phenotype of the model is stable and uniform, the reactivity matching degree with clinical drugs is high, and the method can be widely applied to research and development of anti-osteoporosis drugs and research of pathological mechanisms.

Method and systems for sorting drug-responsive cell population based on single-cell RNA sequencing (scRNA-seq) data are disclosed. In some examples, the method includes: constructing a target gene regulatory network (GRN) for each of the cell populations based on scRNA-seq data of cell populations in a disease state; virtually knocking out targets in the GRN, and constructing a target-perturbed gene regulatory network (tpGRN); acquiring a low-dimensional representation of each of network nodes from the GRN in the GRN and the tpGRN through manifold alignment; calculating a Euclidean distance for each of the network nodes between the GRN and the tpGRN through a Euclidean distance; scoring a drug response of each of the cell populations by comprehensively considering changing trends of a drug target, a 2-hop node, and an edge of the 2-hop node in the GRN and the tpGRN, and determining a sorting result of the drug-responsive cell population.

The present invention relates to a composition for maturation of adrenal organoids, a method for maturation of adrenal organoids using same, and a method for transplantation of organoids prepared by the method. In the present invention, the structurally and functionally mature adrenal organoids prepared under optimized culture conditions using the composition for maturation of adrenal organoids containing adrenocortical hormone and cyclic adenosine monophosphate have been structurally and functionally improved, and it was confirmed that the adrenal organoid chip having a three-dimensional vascular network structure manufactured using the same actually replaces the function of the adrenal gland without side effects after transplantation into a mouse. Accordingly, the present invention can be advantageously used for transplantation or regenerative therapy, drug screening, drug responsiveness evaluation, and the like.

Described are platforms, systems, and methods for screening patients. In one aspect, a computer-implemented method comprises: receiving, from a cellular imaging device, image data comprising calcium kinetic features of neuronal cultures derived from a patient; processing the image data through a machine-learning model to determine a diagnosis for the patient based on the calcium kinetic features, the machine-learning model trained using neuronal calcium data; and providing the diagnosis a user interface.

Technical Problem The purpose of the present invention is to provide a method which enables sex selection in a non-human animal, and enables a coming individual to have no recombination gene, and a transgenic non-human animal giving birth to individuals of only one sex, which is used in the method.Solution to Problem The present disclosure relates to a male transgenic non-human animal in which one of an X chromosome and a Y chromosome comprises an exogenous embryonic death induction gene operatively connected to a drug-responsive promoter. The present disclosure also includes a method for producing a male transgenic non-human animal for sex selection.

The disclosure is directed, in part, to novel drug-responsive T cell factors providing temporal and / or spatial control over T cell (e.g., CAR T cell) activation and / or proliferation, T cells comprising the T cell factors, nucleic acid encoding the T cell factors, and methods for using and producing the same.

The present application relates to a pharmaceutical composition for inhibiting anticancer agent resistance, restoring anticancer agent responsiveness, or enhancing anticancer agent sensitivity, comprising an ODC1 inhibitor as an effective ingredient. Specifically, when EGFR-targeted therapeutic agent resistance was induced using a non-small cell lung cancer cell model in which kinase overexpression is involved and a xenotransplantation animal model thereof, it was confirmed that if ODC1 expression or activity is inhibited, the acquisition of EGFR-targeted therapeutic agent resistance caused by kinase overexpression is inhibited, and the resistance is alleviated, thereby exhibiting an effect of restoring drug responsiveness. Therefore, a preparation that inhibits the expression or activity of the ODC1 can be effectively used as an effective ingredient of a pharmaceutical composition for inhibiting anticancer agent resistance, restoring anticancer agent responsiveness, or enhancing anticancer agent sensitivity.

In a surface-enhanced Raman scattering-based method for testing drug reactivity of cerebrovascular cells, a SERS substrate is manufactured. A SERS substrate array including a plurality of the SERS substrates is manufactured. Cells are cultured on the SERS substrate array. A drug is administered to the cultured cells. A Raman signal is measured from the cells to which the drug is administered. An optimal drug is selected from among the administered drugs on the basis of the measured Raman signal.

Provided herein are methods of predicting the responsiveness of a lymphoma patient to a cancer treatment comprising clustering patients into subgroups of patients using gene expression levels. Also provided herein are methods of treating a lymphoma patient based on predicting the responsiveness of the lymphoma patient to a cancer treatment.

According to embodiments of the present invention, the device and method for calculating gene reproducibility can be provided, the device and method predicting drug reactivity related to a gene in an organoid by using the degree of similarity between an expression pattern of the gene in the organoid and an expression pattern of the gene in a tissue cell. In addition, according to embodiments of the present disclosure, the device and method for calculating gene reproducibility can be provided, the device and method determining an organoid suitable for drug development related to a gene by using an expression pattern of the gene in the organoid.

The present invention relates to a method for efficiently inducing sarcoma cancer in mammals and an animal model of patient-derived xenograft sarcoma cancer produced using such a method. The animal model of the present invention applies the optimal volume and optimal insertion subcutaneous depth of sarcoma tissue to be isolated from the patient and xenotransplanted into the animal, thereby reflecting various biological characteristics such as tumor proliferation, metastasis, and drug responsiveness in the human body with high reliability. Accordingly, the present invention can be usefully used as an efficient analytical means for molecular mechanism research, therapeutic agent screening, and in vivo drug evaluation of sarcoma cancer with unclear pathogenesis and frequent recurrence and metastasis. Furthermore, the present invention relates to a kit for drug responsiveness analysis comprising cancer tissue analogues and the same. The cancer tissue analogue of the present invention efficiently simulates the tumor microenvironment in vivo by solidifying the cell aggregates obtained by three-dimensional culture of cancer cells, especially sarcoma cells, into a Matrigel Matrix, and then forming a vascular endothelial cell channel. Accordingly, the cancer tissue analogue of the present invention can be used as a highly reliable drug screening system by reproducing the drug responsiveness of tumors in vivo with high accuracy, and when established using patient-derived autologous sarcoma cells, the patient's treatment responsiveness to the drug, the response dose, and the optimal combination of drugs can be quickly analyzed in vitro to establish a patient-tailored treatment strategy at an early stage.

The present invention features methods, devices, and kits for detecting gene expression in a patient with a cancer or determining responsive of a patient with a cancer to a treatment, such as treatment with 2X-121 or a pharmaceutically acceptable salt thereof. The invention further includes methods of treating a patient with a cancer by administering a treatment, e.g., treatment with 2X-121 or a pharmaceutically acceptable salt thereof, in particular when the patient is determined to be responsive to the treatment based on the expression of the biomarkers described herein.

The invention discloses a nucleic acid composition, an anti-allergic drug associated diagnosis detection kit and a micro-fluidic chip, and relates to the field of allergy detection. The nucleic acid composition disclosed by the invention realizes multi-target cooperative detection through three-section design: the histamine receptor aptamer specifically recognizes the histamine receptor and triggers the change of a stem-loop structure, and the leukotriene receptor response type DNA skeleton enhances the binding stability with the leukotriene receptor through a repetitive sequence; and the drug-triggered auxiliary chain promotes the formation of the complex by prolonging the tail of the poly (adenylic acid). The three components form a cascade reaction, the inflammatory mediator level and the drug responsiveness can be synchronously detected, the detection is more comprehensive than single target detection, and the structural parametric design ensures the suitability and repeatability.

The disclosure relates to a system comprising software that predicts responsiveness of healthy subjects or subjects at risk for or suffering from Alzheimer's Disease to certain disease modifying drugs. Embodiments of the disclosure include methods comprising analyzing images of the brain for depositions of amyloid-beta (Aβ) protein and tau protein, and correlating protein deposition levels to drug responsiveness.

The invention provides a construction method of a retinal vein occlusion animal model, and belongs to the technical field of medicines. The method comprises the following steps of: performing eyeball surface anesthesia on an anesthetized non-human primate animal, puncturing an eyeball after disinfection to establish two sclera tunnels, respectively inserting an illumination optical fiber and an intraocular laser optical fiber into the two sclera tunnels, then injecting a photosensitizer through limb vein, immediately performing laser photocoagulation on the retinal vein under illumination of the illumination optical fiber after injection, and performing laser photocoagulation on the retinal vein under the illumination of the illumination optical fiber. And obtaining the retinal vein occlusion animal model. According to the method, the retinal vein occlusion model can be successfully constructed, secondary macular edema and vascular recanalization are carried out for a long time and can be maintained for 4-5 weeks, the manifestation sign of retinal hemorrhage after retinal vein occlusion is close to that of human beings, and the method has clinical drug responsiveness, shows the clinical research value and has good application prospects. And a good research model is provided for research in the aspects of etiology, pathology and therapeutics.

What is provided is a nervous system cell-containing spheroid having suitable drug responsiveness. There are provided a nervous system cell-containing spheroid including at least one kind of nerve cells and nervous system cells other than the nerve cells, in which the proportion of the volume of one cell layer positioned at an outer edge of the spheroid to the volume of the entire spheroid is 15% to 30%; a method for producing the nervous system cell-containing spheroid; and a method for evaluating a test substance, the method including incubating a nervous system cell-containing spheroid in the presence of a test substance, and evaluating an effect of the test substance on the nervous system cell-containing spheroid, in which the nervous system cell-containing spheroid includes at least one kind of nerve cells and nervous system cells other than the nerve cells, and the proportion of the volume of one cell layer positioned at an outer edge of the spheroid to the volume of the entire spheroid is 15% to 30%.

Disclosed herein are compositions and methods for identifying a subject at risk for developing heart failure (HF), heart failure with preserved ejection fraction (HFpEF), or heart failure with reduced ejection fraction (HFrEF). Described herein are also methods of treating subjects identified at risk for developing HF, HFpEF, or heart failure with reduced ejection fraction HFrEF.

Described are platforms, systems, and methods for screening patients. In one aspect, a computer-implemented method comprises: receiving, from a cellular imaging device, image data comprising calcium kinetic features of neuronal cultures derived from a patient; processing the image data through a machine-learning model to determine a diagnosis for the patient based on the calcium kinetic features, the machine-learning model trained using neuronal calcium data; and providing the diagnosis a user interface.

The invention belongs to the technical field of tumor biology and organoids, and provides application of PARVA in promoting formation of tumor organoids. The PARVA comprises a PARVA protein or a PARVA coding gene; the application comprises application in preparation of a tumor organoid inducer, a tumor organoid culture kit and construction of a tumor organoid model. According to the invention, the formation efficiency and stability of the tumor organoid can be obviously improved, the difficulty in constructing the organoid with difficult-to-cultivate tumors such as lung cancer and bile duct cancer is solved, and a reliable model is provided for the fundamental research of the tumors; the constructed tumor organ model has a tissue structure, gene characteristics and drug responsiveness which are highly similar to in-vivo tumors, can be used for tumor generation mechanism research, antitumor drug high-throughput screening and clinical personalized treatment scheme evaluation, and has important scientific research value and clinical transformation significance.

The invention discloses a fluorescence quenching probe for targeting tumor cell apoptosis and application of the fluorescence quenching probe. The fluorescent quenching probe for targeting tumor cell apoptosis comprises a Caspase enzyme substrate specific recognition site Asp-Glu-Val-Asp, a fluorescent group, a quenching group and a tumor specific peptide fragment ligand P160. According to the invention, tumor drug response and immune infiltration and killing effect can be visually represented, and based on tumor cell endocytosis effect, the marking efficiency is significantly higher than that of a conventional probe. The method can be used for breast tumor drug response mechanism or toxicology research and anti-tumor immune polarization research. Compared with a traditional drug sensitive detection system, the tumor cell apoptosis can be monitored in real time, and the drug responsiveness can be detected in a shorter time; and the immune killing effect can be quantitatively evaluated by realizing targeted detection of tumor killing under a complex organ-like model. The probe is combined with a microwell plate technology, so that micro-scale, visual and quantitative research of drug sensitivity detection can be realized.

The present invention features methods, devices, and kits for detecting gene expression in a patient with a cancer or determining responsive of a patient with a cancer to a treatment, such as treatment with 2X-121 or a pharmaceutically acceptable salt thereof. The invention further includes methods of treating a patient with a cancer by administering a treatment, e.g., treatment with 2X-121 or a pharmaceutically acceptable salt thereof, in particular when the patient is determined to be responsive to the treatment based on the expression of the biomarkers described herein.

The present invention relates to a pharmaceutical composition for inhibiting anticancer drug tolerance, recovering anticancer drug responsiveness, or enhancing anticancer drug sensitivity, the composition containing an ODC1 inhibitor as an active ingredient. More specifically, it was found that if ODC1 expression or activity is inhibited when inducing EGFR-targeting drug tolerance using a non-small cell lung cancer cell model overexpressing a kinase involved in EGFR-targeting drug tolerance induction and an animal model xenografted with same, the acquisition of EGFR-targeting drug tolerance caused by kinase overexpression is inhibited and the tolerance is alleviated, and thus drug responsiveness is recovered. Therefore, an agent that inhibits the ODC1 expression or activity can be effectively used as an effective ingredient in a pharmaceutical composition for inhibiting anticancer drug tolerance, recovering anticancer drug responsiveness, or enhancing anticancer drug sensitivity.

The purpose of embodiments disclosed in the present specification is to provide an apparatus and a method for selecting, from among a large number of organoids, an organoid suitable for a drug experiment on a specific gene. In addition, the purpose of embodiments disclosed in the present specification is to provide an apparatus and a method for calculating a drug responsiveness value for a specific gene of organoids by utilizing RNAsep data, which is genetic data.